Blandine Gatta-Cherifi

Bordeaux, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 49 publications

Title Not Found

Title Not Found

Journal: Sante publique (Vandoeuvre-les-Nancy, France)

Published: August 03, 2026

SEMASEARCH Study Design: Real-World Evaluation of Semaglutide 2.4 mg in Adults With Severe Obesity Underrepresented in Clinical Trials.

SEMASEARCH Study Design: Real-World Evaluation of Semaglutide 2.4 mg in Adults With Severe Obesity Underrepresented in Clinical Trials.

Journal: Diabetes, obesity & metabolism

Published: January 06, 2026

Impact of eating behaviour on craniopharyngioma-associated obesity.

Impact of eating behaviour on craniopharyngioma-associated obesity.

Journal: Journal of pediatric endocrinology & metabolism : JPEM

Published: October 14, 2025

Low back pain, disability and sagittal alignment of obese patients before and after bariatric surgery: A comparative study.

Low back pain, disability and sagittal alignment of obese patients before and after bariatric surgery: A comparative study.

Journal: Clinical neurology and neurosurgery

Published: August 14, 2025

Glycemic and renal effects of SGLT2 Inhibitors in Prader-Willi syndrome: Benefits and risks.

Glycemic and renal effects of SGLT2 Inhibitors in Prader-Willi syndrome: Benefits and risks.

Journal: Diabetes & metabolism

Published: July 18, 2025

Effectiveness and safety of GLP-1 receptor agonists in craniopharyngioma patients with obesity: A multicentre real-world study.

Effectiveness and safety of GLP-1 receptor agonists in craniopharyngioma patients with obesity: A multicentre real-world study.

Journal: Diabetes, obesity & metabolism

Published: June 30, 2025

Targeted Next-Generation Sequencing of the Leptin-Melanocortin Pathway in Severe Obesity.

Targeted Next-Generation Sequencing of the Leptin-Melanocortin Pathway in Severe Obesity.

Journal: Obesity (Silver Spring, Md.)

Published: June 08, 2025

Targeted Next-Generation Sequencing of the Leptin-Melanocortin Pathway in Severe Obesity.

Targeted Next-Generation Sequencing of the Leptin-Melanocortin Pathway in Severe Obesity.

Journal: Obesity (Silver Spring, Md.)

Published: June 08, 2025

Biallelic pathogenic variants in POMC can cause combined pituitary hormonal deficiency associated with severe obesity.

Biallelic pathogenic variants in POMC can cause combined pituitary hormonal deficiency associated with severe obesity.

Journal: European journal of endocrinology

Published: April 05, 2025

Semaglutide 2.4 mg in French people living with Class 3 obesity and comorbidities: Baseline characteristics and real-world safety data.

Semaglutide 2.4 mg in French people living with Class 3 obesity and comorbidities: Baseline characteristics and real-world safety data.

Journal: Diabetes & metabolism

Published: November 14, 2024

Diagnosis and management of children and adult craniopharyngiomas: A French Endocrine Society/French Society for Paediatric Endocrinology & Diabetes Consensus Statement.

Diagnosis and management of children and adult craniopharyngiomas: A French Endocrine Society/French Society for Paediatric Endocrinology & Diabetes Consensus Statement.

Journal: Annales d'endocrinologie

Published: June 16, 2024

Semaglutide Treatment in a Patient with Extreme Obesity and Massive Lymphedema: A Case Report.

Semaglutide Treatment in a Patient with Extreme Obesity and Massive Lymphedema: A Case Report.

Journal: Obesity facts

Published: March 07, 2024

Showing 1-12 of 49

Last Updated: 09/26/2026